Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefepime + taniborbactam
- Development stage
- Preclinical
- Lead developer
- Venatorx Pharmaceuticals
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Cefepime + taniborbactam is an investigational intravenous combination antibiotic consisting of cefepime, a fourth-generation cephalosporin beta-lactam antibiotic, and taniborbactam (formerly VNRX-5133), a novel bicyclic boronate beta-lactamase inhibitor. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Taniborbactam inhibits both serine and metallo-beta-lactamases (Ambler classes A, B [NDM, VIM], C, and D), thereby protecting cefepime from enzymatic degradation by resistant bacteria. This combination is being developed primarily for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis, as well as hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults. It targets serious infections caused by multidrug-resistant gram-negative bacteria such as carbapenem-resistant Enterobacterales (CRE) and multidrug-resistant Pseudomonas aeruginosa[1][2][3][4][5][8].
- Brand names
- Exblifep
- Other names
- cefepime-taniborbactam
02
Targets
β-lactamaseNeuraminidase
Beyond the preview
Go deeper on cefepime + taniborbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefepime + taniborbactam.